Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Trial Profile

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs CYC 065 (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 09 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 04 Oct 2018 Status changed from planning to not yet recruiting, according to a Cyclacel Pharmaceuticals media release.
    • 04 Oct 2018 According to a Cyclacel Pharmaceuticals media release, the company has received approval from institutional review board (IRB) for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top